Kalaris Therapeutics, Inc. (KLRS)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $37.49M
Last updated: Nov 17, 2026 at 11:05 AM ET
Kalaris Therapeutics, Inc. (KLRS) Earnings: Report Dates and Results
Kalaris Therapeutics (KLRS) is expected to report earnings on Mar 15, 2027. In the quarter ended Sep 30, 2026, Kalaris Therapeutics reported EPS of -$0.46, above the -$0.52 estimate. It beat the EPS estimate in 4 of the last 8 quarters.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
KLRS has an expected report date of Mar 15, 2027.
Earnings History
Of the 27 quarters below that had an estimate, KLRS beat 8, missed 5 and matched 14. The widest gap in the table came in the quarter ended Sep 30, 2024, when EPS landed 765.58% below the estimate.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported |
|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | -$0.46 | -$0.52 | -$0.57 - -$0.40 | +11.54% | Beat | N/A | 8 | 4 up, 2 down | Nov 10, 2026 |
| Jun 30, 2026 | -$0.48 | -$0.50 | -$0.55 - -$0.38 | +4.00% | Beat | N/A | 8 | 1 up, 0 down | Aug 11, 2026 |
| Mar 31, 2026 | -$0.46 | -$0.52 | -$0.61 - -$0.43 | +11.54% | Beat | N/A | 6 | 3 up, 0 down | May 12, 2026 |
| Dec 31, 2025 | -$0.44 | -$0.55 | -$0.73 - -$0.17 | +20.00% | Beat | N/A | 6 | 2 up, 0 down | Mar 17, 2026 |
| Sep 30, 2025 | -$0.64 | -$0.61 | -$1.81 - -$0.60 | -4.92% | Miss | N/A | 2 | 0 up, 0 down | Nov 12, 2025 |
| Jun 30, 2025 | -$0.61 | -$0.52 | N/A | -17.31% | Miss | N/A | 2 | 0 up, 1 down | Aug 13, 2025 |
| Mar 31, 2025 | -$2.52 | -$0.77 | N/A | -227.27% | Miss | N/A | N/A | N/A | May 14, 2025 |
| Dec 31, 2024 | -$3.28 | -$2.76 | N/A | -18.90% | Miss | N/A | N/A | N/A | Mar 7, 2025 |
| Sep 30, 2024 | -$0.82 | -$0.10 | N/A | -765.58% | Miss | N/A | N/A | N/A | Nov 12, 2024 |
| Jun 30, 2024 | -$0.05 | -$0.05 | N/A | 0.00% | In line | N/A | N/A | N/A | Aug 1, 2024 |
| Mar 31, 2024 | -$0.26 | -$0.26 | N/A | 0.00% | In line | N/A | N/A | N/A | May 2, 2024 |
| Dec 31, 2023 | -$0.52 | -$0.52 | N/A | 0.00% | In line | N/A | N/A | N/A | Feb 8, 2024 |
| Sep 30, 2023 | -$0.39 | -$0.39 | N/A | 0.00% | In line | N/A | N/A | N/A | Nov 2, 2023 |
| Jun 30, 2023 | -$0.48 | -$0.48 | N/A | 0.00% | In line | N/A | N/A | N/A | Aug 3, 2023 |
| Mar 31, 2023 | -$0.44 | -$0.47 | N/A | +6.38% | Beat | N/A | N/A | N/A | Jun 29, 2023 |
| Dec 31, 2022 | -$0.32 | -$0.32 | N/A | 0.00% | In line | N/A | N/A | N/A | Mar 30, 2023 |
| Sep 30, 2022 | -$0.50 | -$0.50 | N/A | 0.00% | In line | N/A | N/A | N/A | Nov 3, 2022 |
| Jun 30, 2022 | -$0.69 | -$0.69 | N/A | 0.00% | In line | N/A | N/A | N/A | Aug 4, 2022 |
| Mar 31, 2022 | -$0.69 | -$0.69 | N/A | 0.00% | In line | N/A | N/A | N/A | Jun 29, 2022 |
| Dec 31, 2021 | -$0.92 | -$0.92 | N/A | 0.00% | In line | N/A | N/A | N/A | Mar 30, 2022 |
| Sep 30, 2021 | -$0.72 | -$0.72 | N/A | 0.00% | In line | N/A | N/A | N/A | Nov 5, 2021 |
| Jun 30, 2021 | -$0.60 | -$0.60 | N/A | 0.00% | In line | N/A | N/A | N/A | Aug 6, 2021 |
| Mar 31, 2021 | -$0.50 | -$0.50 | N/A | 0.00% | In line | N/A | N/A | N/A | Jun 29, 2021 |
| Dec 31, 2020 | -$0.41 | -$0.44 | N/A | +6.82% | Beat | N/A | N/A | N/A | Mar 30, 2021 |
| Sep 30, 2020 | -$0.58 | -$0.58 | N/A | 0.00% | In line | N/A | N/A | N/A | Nov 10, 2020 |
| Jun 30, 2020 | -$0.34 | -$4.43 | N/A | +92.33% | Beat | N/A | N/A | N/A | Jul 6, 2020 |
| Mar 31, 2020 | -$4.21 | -$4.60 | N/A | +8.43% | Beat | N/A | N/A | N/A | Jun 29, 2020 |
Estimates made before a stock split are shown on the same share basis as the reported EPS.
Annual EPS
EPS for the fiscal year ended Dec 31, 2025 was -$4.21, after -$4.41 the year before. It was -$5.54 for the year ended Dec 31, 2020, the oldest of the 6 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2025 | -$4.21 | N/A |
| Dec 31, 2024 | -$4.41 | N/A |
| Dec 31, 2023 | -$1.83 | N/A |
| Dec 31, 2022 | -$2.20 | N/A |
| Dec 31, 2021 | -$2.74 | N/A |
| Dec 31, 2020 | -$5.54 | N/A |
Frequently Asked Questions About KLRS
When is Kalaris Therapeutics's next earnings date?
Kalaris Therapeutics's next earnings report is expected for Mar 15, 2027.
Did KLRS beat earnings estimates last quarter?
Yes. Kalaris Therapeutics reported EPS of -$0.46 for the quarter ended Sep 30, 2026, above the -$0.52 estimate, a 11.54% surprise.
What EPS do analysts expect from KLRS next quarter?
The consensus EPS estimate for Kalaris Therapeutics for the quarter ending Dec 31, 2026 is -$0.52 from 10 analysts, with estimates from -$0.56 to -$0.49.
How often does KLRS beat earnings estimates?
Kalaris Therapeutics beat the EPS estimate in 4 of the last 8 quarters, with an average surprise of -27.67%.
KLRS pages: Overview, Earnings, Forecast, Financials, Competitors